Tepmetko 225mg Tablet Abu Dhabi | Top Pharma Exporter from India

Tepmetko 225mg Tablet: Specialized MET Inhibitor for Advanced NSCLC

Are you seeking a reliable Tepmetko 225 mg tablet exporter from India? Ernest Oncology, a premier division of Ernest Pharmaceutical Pvt. Ltd., is a leading global supplier and bulk distributor of targeted cancer therapies. We maintain a robust, regulatory-compliant supply chain serving the UK (London), USA, UAE (Abu Dhabi), Australia, and South Africa, ensuring that high-specification oncology medications reach healthcare providers with pharmaceutical-grade integrity and global logistics expertise.

Detailed Product Overview: What is Tepmetko 225mg?

Tepmetko 225mg (Tepotinib) is a highly selective, once-daily oral MET (Mesenchymal-Epithelial Transition) tyrosine kinase inhibitor. It is specifically engineered to target the oncogenic MET receptor signaling caused by MET exon 14 (METex14) skipping alterations. These genetic mutations lead to the production of a dysfunctional protein that drives uncontrolled cell growth and metastasis.

As the first oral MET inhibitor to receive regulatory approval globally, Tepmetko represents a breakthrough in precision oncology for patients with aggressive lung tumors that previously had a poor prognosis.

Primary Therapeutic Indications: 

Tepmetko 225 mg is clinically indicated for the treatment of the following:

1. Metastatic Non-Small Cell Lung Cancer (NSCLC): Specifically for adult patients whose tumors harbor MET exon 14 skipping alterations.

2. Advanced NSCLC: It is approved for use in both treatment-naïve (first-line) patients and those who have previously received treatment but experienced disease progression.

Mechanism of Action: How Tepmetko 225 mg Works: 

Tepmetko functions through a highly targeted biochemical mechanism:

• MET Receptor Inhibition: It selectively binds to the ATP-binding site of the MET tyrosine kinase. By blocking this site, it prevents the phosphorylation and activation of the MET receptor.

• Disrupting Signaling Pathways: By inhibiting MET activation, Tepmetko halts the downstream signaling pathways (such as PI3K/Akt and MAPK/ERK) that are responsible for tumor cell proliferation, survival, and migration.

• Tumor Regression: The inhibition of these "growth signals" results in decreased tumor growth and can lead to significant tumor shrinkage (regression) in MET-dependent cancers.

Administration and Safety Guidelines: 

• Standard Dosage: The recommended adult dose is 450mg once daily, administered as two 225mg tablets.

• Instructions: Tablets must be taken with food at approximately the same time every day. They should be swallowed whole. Do not crush, chew, or split the tablets.

• Missed Dose: If a dose is missed and the next dose is more than 8 hours away, take it immediately. Otherwise, skip the missed dose and resume the regular schedule.

• Safety Monitoring: Healthcare providers will regularly monitor the following:

  • Lung Health: For signs of Interstitial Lung Disease (ILD) or pneumonitis.

  • Liver Function: Monitoring ALT, AST, and bilirubin levels.

  • Pancreatic Health: Monitoring amylase and lipase levels.

• Contraception: Patients of reproductive potential should use effective birth control during treatment and for at least one week after the final dose.

Why Source Tepmetko 225 mg from Ernest Oncology?

• Strategic Indian Exporter: We provide direct access to high-quality, GMP-compliant pharmaceutical supplies with significant cost-efficiencies for bulk B2B procurement.

• Global Distribution Reach: Expertise in navigating the regulatory and customs requirements of the USA, UK, UAE, Australia, and South Africa. 

• Uninterrupted Supply Chain: We specialize in managing high-value cold chain and standard oncology logistics to ensure treatment continuity for clinics and hospitals.

• B2B Partnership Focus: We are the preferred partner for international pharmaceutical wholesalers, government health tenders, and private oncology centers.